CREO.L vs. SPY

Last updated Jun 5, 2026

CREO.L (Creo Medical Group plc) is a stock, while SPY (State Street SPDR S&P 500 ETF) is S&P 500 fund tracking the S&P 500 Index. Over the past 5 years, CREO.L returned -41.97%/yr vs 15.14%/yr for SPY. At a 0.03 correlation, their price movements are largely independent.

Performance

CREO.L vs. SPY - Performance Comparison

The chart below illustrates the hypothetical performance of a £10,000 investment in Creo Medical Group plc (CREO.L) and State Street SPDR S&P 500 ETF (SPY). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

CREO.L is traded in GBp, while SPY is traded in USD. To make them comparable, the SPY values have been converted to GBp using the latest available exchange rates.

Returns By Period

In the year-to-date period, CREO.L achieves a 38.89% return, which is significantly higher than SPY's 11.78% return.

CREO.L

• 1D: 0.00%
• 1M: 13.40%
• YTD: 38.89%
• 6M: 32.53%
• 1Y: -14.06%
• 3Y*: -17.23%
• 5Y*: -41.97%
• 10Y*: —

SPY

• 1D: 0.00%
• 1M: 4.50%
• YTD: 11.78%
• 6M: 10.31%
• 1Y: 30.60%
• 3Y*: 19.38%
• 5Y*: 15.14%
• 10Y*: 16.39%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CREO.L vs. SPY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CREO.L Creo Medical Group plc	38.89%	-49.23%	-57.61%	82.18%	-83.05%	-23.20%	7.18%	-9.05%	186.33%	-14.72%
SPY State Street SPDR S&P 500 ETF	9.54%	9.33%	27.07%	19.87%	-8.45%	29.95%	14.86%	26.23%	1.09%	11.18%

Correlation

The correlation between CREO.L and SPY is 0.03, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.03
Correlation (3Y) Calculated over the trailing 3-year period	-0.00
Correlation (5Y) Calculated over the trailing 5-year period	0.03
Correlation (All Time) Calculated using the full available price history since Dec 12, 2016	0.03

Return for Risk

CREO.L vs. SPY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CREO.L

CREO.L Risk / Return Rank: 30
CREO.L Sharpe Ratio Rank: 30
CREO.L Sortino Ratio Rank: 30
CREO.L Omega Ratio Rank: 30
CREO.L Calmar Ratio Rank: 30
CREO.L Martin Ratio Rank: 32

SPY

SPY Risk / Return Rank: 66
SPY Sharpe Ratio Rank: 66
SPY Sortino Ratio Rank: 63
SPY Omega Ratio Rank: 66
SPY Calmar Ratio Rank: 60
SPY Martin Ratio Rank: 73

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CREO.L vs. SPY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Creo Medical Group plc (CREO.L) and State Street SPDR S&P 500 ETF (SPY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CREO.L	SPY	Difference
Sharpe ratio: Return per unit of total volatility	-0.25	2.69	-2.94
Sortino ratio: Return per unit of downside risk	-0.01	3.46	-3.47
Omega ratio: Gain probability vs. loss probability	1.00	1.51	-0.51
Calmar ratio: Return relative to maximum drawdown	-0.34	4.00	-4.34
Martin ratio: Return relative to average drawdown	-0.53	15.30	-15.83
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CREO.L vs. SPY - Sharpe Ratio Comparison

The current CREO.L Sharpe Ratio is -0.25, which is lower than the SPY Sharpe Ratio of 2.69. The chart below compares the historical Sharpe Ratios of CREO.L and SPY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	CREO.L	SPY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.25	2.69	-2.94
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.74	0.95	-1.69
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.91	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.33	0.69	-1.03

Drawdowns

CREO.L vs. SPY - Drawdown Comparison

The maximum CREO.L drawdown since its inception was -96.07%, which is greater than SPY's maximum drawdown of -34.68%. Use the drawdown chart below to compare losses from any high point for CREO.L and SPY.

Drawdown Indicators

	CREO.L	SPY	Difference
Max Drawdown Largest peak-to-trough decline	-96.07%	-34.68%	-61.39%
Max Drawdown (1Y) Largest decline over 1 year	-41.41%	-7.69%	-33.72%
Max Drawdown (3Y) Largest decline over 3 years	-80.15%	-21.94%	-58.21%
Max Drawdown (5Y) Largest decline over 5 years	-95.66%	-21.94%	-73.72%
Max Drawdown (10Y) Largest decline over 10 years	—	-25.78%	—
Current Drawdown Current decline from peak	-94.34%	0.00%	-94.34%
Average Drawdown Average peak-to-trough decline	-51.61%	-4.77%	-46.84%
Ulcer Index Depth and duration of drawdowns from previous peaks	26.45%	2.00%	+24.45%

Volatility

CREO.L vs. SPY - Volatility Comparison

Creo Medical Group plc (CREO.L) has a higher volatility of 26.78% compared to State Street SPDR S&P 500 ETF (SPY) at 2.44%. This indicates that CREO.L's price experiences larger fluctuations and is considered to be riskier than SPY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CREO.L	SPY	Difference
Volatility (1M) Calculated over the trailing 1-month period	26.78%	2.44%	+24.34%
Volatility (6M) Calculated over the trailing 6-month period	46.42%	8.11%	+38.31%
Volatility (1Y) Calculated over the trailing 1-year period	56.05%	11.47%	+44.58%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	56.96%	16.01%	+40.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	50.77%	18.02%	+32.75%

Dividends

CREO.L vs. SPY - Dividend Comparison

CREO.L has not paid dividends to shareholders, while SPY's dividend yield for the trailing twelve months is around 1.00%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
CREO.L Creo Medical Group plc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SPY State Street SPDR S&P 500 ETF	1.00%	1.07%	1.21%	1.40%	1.65%	1.20%	1.52%	1.75%	2.04%	1.80%	2.03%	2.06%

Frequently Asked Questions

Can I hold both CREO.L and SPY in my portfolio?

CREO.L and SPY have a correlation of 0.03, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.